Cost-Utility Analysis: Current Methodological Issues and Future Perspectives
The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. There is a lack of consensus on main methodological issues and consequently we may question the appropriateness of the use of...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Frontiers Research Foundation
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113167/ |